SEC Form 4 · accession 0001193125-26-384878
Ultragenyx Pharmaceutical Inc. · RARE
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Theodore Alan Huizenga
Officer — SVP, Chief Accounting Officer
Period of report
Sep 3, 2026
Accepted (ET)
Sep 8, 2026 · 12:29 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001515673
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1,F2,F3 | Sep 3, 2026 | S | 161 | $13.99 | D | 69,146 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Represents shares sold to pay required tax withholdings due to the vesting of RSUs.
- F2Includes 396 shares acquired under the Company's Amended and Restated Employee Stock Purchase Place on April 30, 2026.
- F3Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions.